治疗向努迪克斯酸酶1会产生MYC驱动的代谢脆弱性
Minhui Ye1,2, Yingzhe Fang1,2, Lu Chen2
1Department of Urology, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, 430071, China.
Nature communications
|March 17, 2024
概括
癌细胞重新连接新陈代谢以生长,增加活性氧物种 (ROS). 针对MYC驱动的酶NUDT1,破坏了这种平衡,提供了一种新的癌症治疗策略.
科学领域:
- 生物化学 生化学
- 癌症生物学 癌症生物学
- 代谢途径 代谢途径
背景情况:
- 瘤细胞表现出高的增殖率,需要显著的核酸合成.
- 在癌细胞中增加反应性氧物种 (ROS) 的产生矛盾地损害了DNA和脱氧核糖三酸盐 (dNTP).
- 核酸合成和ROS生成在瘤发生中的整合尚未完全理解.
研究的目的:
- 为了研究MYC驱动癌症的代谢依赖性.
- 确定参与协调核酸代谢和ROS生成的关键酶.
- 探索NUDT1作为MYC驱动癌症的潜在治疗标.
主要方法:
- 一个基于集群定期间隔的短Palindromic重复 (CRISPR) 的功能屏幕被用来准代谢基因.
- 研究了MYC,NOX4-ROS通道和PLK1-NUDT1通道之间的机制联系.
- 在临床前模型中开发并测试了一种新的NUDT1降解剂LC-1-40.
主要成果:
- 纽迪克斯酸酶1 (NUDT1) 被确定为一种关键的MYC驱动的代谢依赖.
- 发现MYC可以调节NOX4-ROS和PLK1-NUDT1通路之间的平衡.
- 在体内,LC-1-40有效地消耗了NUDT1,导致过度的核酸氧化和细胞毒性.
- 在用LC-1-40治疗的患者衍生的异种移植中观察到治疗反应.
结论:
- 针对NUDT1是一种可行的治疗策略,用于MYC驱动的癌症.
- 对NUDT1的药理抑制利用了癌细胞中的代谢脆弱性.
- ROS生成和核酸消毒之间的相互作用对癌细胞生存至关重要.
相关概念视频
Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


